The Medicines Company (Nasdaq: MDCO) reported earnings on July 24. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), The Medicines Company beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased significantly. Non-GAAP earnings per share grew. GAAP earnings per share grew significantly.

Gross margins dropped, operating margins grew, net margins grew.

Revenue details
 The Medicines Company notched revenue of $172.8 million. The 10 analysts polled by S&P Capital IQ predicted sales of $168.7 million on the same basis. GAAP reported sales were 27% higher than the prior-year quarter's $135.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.50. The eight earnings estimates compiled by S&P Capital IQ predicted $0.48 per share. Non-GAAP EPS of $0.50 for Q2 were 8.7% higher than the prior-year quarter's $0.46 per share. GAAP EPS of $0.30 for Q2 were 20% higher than the prior-year quarter's $0.25 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 63.0%, 550 basis points worse than the prior-year quarter. Operating margin was 16.7%, 230 basis points better than the prior-year quarter. Net margin was 10.5%, 40 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $173.9 million. On the bottom line, the average EPS estimate is $0.59.

Next year's average estimate for revenue is $686.3 million. The average EPS estimate is $1.92.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 161 members out of 177 rating the stock outperform, and 16 members rating it underperform. Among 53 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give The Medicines Company a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on The Medicines Company is outperform, with an average price target of $37.95.